Correlation Between Inozyme Pharma and Immunome
Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Immunome at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Immunome into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inozyme Pharma and Immunome, you can compare the effects of market volatilities on Inozyme Pharma and Immunome and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Immunome. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Immunome.
Diversification Opportunities for Inozyme Pharma and Immunome
0.63 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Inozyme and Immunome is 0.63. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Immunome in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Immunome and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Immunome. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Immunome has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Immunome go up and down completely randomly.
Pair Corralation between Inozyme Pharma and Immunome
Given the investment horizon of 90 days Inozyme Pharma is expected to under-perform the Immunome. In addition to that, Inozyme Pharma is 1.3 times more volatile than Immunome. It trades about -0.25 of its total potential returns per unit of risk. Immunome is currently generating about -0.11 per unit of volatility. If you would invest 1,028 in Immunome on December 29, 2024 and sell it today you would lose (329.00) from holding Immunome or give up 32.0% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Significant |
Accuracy | 100.0% |
Values | Daily Returns |
Inozyme Pharma vs. Immunome
Performance |
Timeline |
Inozyme Pharma |
Immunome |
Inozyme Pharma and Immunome Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Inozyme Pharma and Immunome
The main advantage of trading using opposite Inozyme Pharma and Immunome positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Immunome can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunome will offset losses from the drop in Immunome's long position.Inozyme Pharma vs. Day One Biopharmaceuticals | Inozyme Pharma vs. X4 Pharmaceuticals | Inozyme Pharma vs. Acumen Pharmaceuticals | Inozyme Pharma vs. Mereo BioPharma Group |
Immunome vs. Anebulo Pharmaceuticals | Immunome vs. Adagene | Immunome vs. Acrivon Therapeutics, Common | Immunome vs. AnaptysBio |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Complementary Tools
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |